Colon carcinogenesis: Influence of western diet-induced obesity and targeting stem cells using dietary bioactive compounds

Nutrition

Volumn 30, Issue 11-12, 2014, Pages 1242-1256

  Kasdagly, Maria ^a   Radhakrishnan, Sridhar ^a,b   Reddivari, Lavanya ^b   Veeramachaneni, D N Rao ^a   Vanamala, Jairam ^b  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Colon cancer; Curcumin; Grape seed extract; IGF 1; Insulin; LGR5, ALDH1B1; Lycopene; Resveratrol; Stem cells; Western diet; Wnt

Indexed keywords

ALDEHYDE DEHYDROGENASE 1 B1; ALDEHYDE DEHYDROGENASE ISOENZYME 1; APC PROTEIN; BETA CATENIN; CURCUMIN; FLUOROURACIL; FOLINIC ACID; G PROTEIN COUPLED RECEPTOR; GRAPE SEED EXTRACT; INSULIN; LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR 5; LYCOPENE; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RESVERATROL; SOMATOMEDIN C; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAROTENOID; STILBENE DERIVATIVE;

ABERRANT CRYPT FOCUS; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RECURRENCE; CANCER STEM CELL; COLON CANCER; COLON CARCINOGENESIS; COLON STEM CELL; DRUG SCREENING; DRUG STRUCTURE; FAMILIAL COLON POLYPOSIS; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR 5 GENE; NONHUMAN; OBESITY; REVIEW; STEM CELL NICHE; TUMOR MODEL; TUMOR REGRESSION; TUMOR RESISTANCE; WEIGHT GAIN; WNT SIGNALING PATHWAY; ADVERSE EFFECTS; ANIMAL; COLONIC NEOPLASMS; COMPLICATION; DRUG EFFECTS; PHYTOTHERAPY; WESTERN DIET;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAROTENOIDS; COLONIC NEOPLASMS; CURCUMIN; DIET, WESTERN; GRAPE SEED EXTRACT; HUMANS; NEOPLASTIC STEM CELLS; OBESITY; PHYTOTHERAPY; STILBENES;

EID: 84908146555     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2014.02.016     Document Type: Review

References (146)

1. Huerta S., Goulet E.J., Livingston E.H. Colon cancer and apoptosis. Am J Surg 2006, 191:517-526.
2. Group UCSW. United States Cancer Statistics (USCS): 1999-2007 incidence and mortality data. 2010. Available from: . Accessed November 10, 2013. http://apps.nccd.cdc.gov/uscs/.
3. Howlader N., Noone A., Krapcho M., Neyman N., Aminou R., Waldron W., et al. SEER Cancer Statistics Review, 1975-2008 2011, National Cancer Institute, Bethesda, MD.
4. Wicha M.S., Liu S.L., Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res 2006, 66:1883-1890.
5. Kemper K., Grandela C., Medema J.P. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 2010, 1:387-395.
6. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Cacerescortes J., et al. A cell initiating human acute myeloid-leukemia after transplantation into Scid mice. Nature 1994, 367:645-648.
7. Anderson E.C., Hessman C., Levin T.G., Monroe M.M., Wong M.H. The role of colorectal cancer stem cells in metastatic disease and therapeutic response. Cancers 2011, 3:319-339.
8. Yu Y., Kanwar S.S., Patel B.B., Nautiyal J., Sarkar F.H., Majumdar A.P.N. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol 2009, 2:321-328.
9. Barker N., Van Es J.H., Kuipers J., Kujala P., Van Den Born M., Cozijnsen M., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449:1003-1007.
10. Chen Y., Orlicky D.J., Matsumoto A., Singh S., Thompson D.C., Vasiliou V. Aldehyde dehydrogenase 1B1 (ALDH1B1) is a potential biomarker for human colon cancer. Biochem Biophys Res Commun 2011, 405:172-179.
11. Marchitti S.A., Brocker C., Stagos D., Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 2008, 4:697-720.
12. Zeng H., Lazarova D.L. Obesity-related colon cancer: dietary factors and their mechanisms of anticancer action. Clin Exp Pharmacol Physiol 2012, 39:161-167.
13. Kaaks R., Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001, 60:91-106.
14. Marshall J.R. Prevention of colorectal cancer: diet, chemoprevention, and lifestyle. Gastroenterol Clin North Am 2008, 37:73-82.
15. Bruce W.R., Wolever T.M., Giacca A. Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. Nutr Cancer 2000, 37:19-26.
16. Cappellani A., Zanghi A., Di Vita M., Cavallaro A., Piccolo G., Veroux P., et al. Strong correlation between diet and development of colorectal cancer. Front Biosci 2013, 18:190-198.
17. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
18. Liang J., Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2:339-345.
19. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004.
20. Desbois-Mouthon C., Cadoret A., Blivet-Van Eggelpoel M.J., Bertrand F., Cherqui G., Perret C., et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001, 20:252-259.
21. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007, 17:45-51.
22. Sanders L.M., Henderson C.E., Hong M.Y., Barhoumi R., Burghardt R.C., Wang N., et al. An increase in reactive oxygen species by dietary fish oil coupled with the attenuation of antioxidant defenses by dietary pectin enhances rat colonocyte apoptosis. J Nutr 2004, 134:3233-3238.
23. Smith K., Bui T.D., Poulsom R., Kaklamanis L., Williams G., Harris A.L. Up-regulation of macrophage wnt gene expression in adenoma-carcinoma progression of human colorectal cancer. Br J Cancer 1999, 81:496-502.
24. Platz E.A., Willett W.C., Colditz G.A., Rimm E.B., Spiegelman D., Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control 2000, 11:579-588.
25. Anand P., Kunnumakara A.B., Sundaram C., Harikumar K.B., Tharakan S.T., Lai O.S., et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 2008, 25:2097-2116.
26. Newmark H.L., Yang K., Kurihara N., Fan K., Augenlicht L.H., Lipkin M. Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis 2009, 30:88-92.
27. Erdelyi I., Levenkova N., Lin E.Y., Pinto J.T., Lipkin M., Quimby F.W., et al. Western-style diets induce oxidative stress and dysregulate immune responses in the colon in a mouse model of sporadic colon cancer. J Nutr 2009, 139:2072-2078.
28. Zhou B.B.S., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nature Rev Drug Discov 2009, 8:806-823.
29. Kawasaki B.T., Hurt E.M., Mistree T., Farrar W.L. Targeting cancer stem cells with phytochemicals. Mol Interv 2008, 8:174-184.
30. Li Y.Y., Wicha M.S., Schwart S.J., Sun D.X. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem 2011, 22:799-806.
31. Park C.H., Hahm E.R., Park S., Kim H.K., Yang C.H. The inhibitory mechanism of curcumin and its derivative against [beta]-catenin/Tcf signaling. FEBS lett 2005, 579:2965-2971.
32. Yan C., Jamaluddin M.S., Aggarwal B., Myers J., Boyd D.D. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Canc Ther 2005, 4:233-241.
33. Kakarala M., Brenner D.E., Korkaya H., Cheng C., Tazi K., Ginestier C., et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 2010, 122:777-785.
34. Tang F.Y., Shih C.J., Cheng L.H., Ho H.J., Chen H.J. Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway. Mol Nutr Food Res 2008, 52:646-654.
35. Hope C., Planutis K., Planutiene M., Moyer M.P., Johal K.S., Woo J., et al. Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: Implications for colon cancer prevention. Mol Nutr Food Res 2008, 52:S52-S61.
36. Cecchinato V., Chiaramonte R., Nizzardo M., Cristofaro B., Basile A., Sherbet G.V., et al. Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem Pharmacol 2007, 74:1568-1574.
37. Vanamala J., Reddivari L., Radhakrishnan S., Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010, 10:238.
38. Engelbrecht A.M., Mattheyse M., Ellis B., Loos B., Thomas M., Smith R., et al. Proanthocyanidin from grape seeds inactivates the PI3-kinase/PKB pathway and induces apoptosis in a colon cancer cell line. Cancer Lett 2007, 258:144-153.
39. Velmurugan B., Singh R.P., Agarwal R., Agarwal C. Dietary-feeding of grape seed extract prevents azoxymethane-induced colonic aberrant crypt foci formation in Fischer 344 Rats. Mol Carcinog 2010, 49:641-652.
40. Velmurugan B., Singh R.P., Kaul N., Agarwal R., Agarwal C. Dietary feeding of grape seed extract prevents intestinal tumorigenesis in APC(min/+) mice. Neoplasia 2010, 12:95-102.
41. Bagchi D., Bagchi M., Stohs S.J., Ray S.D., Sen C.K., Preuss H.G. Cellular protection with proanthocyanidins derived from grape seeds. Alcohol and wine in health and disease 2002, 260-270. New York Academy of Science, New York. D.K. Das, F. Ursini (Eds.).
42. Faria A., Calhau C., de Freitas V., Mateus N. Procyanidins as antioxidants and tumor cell growth modulators. J Agric Food Chem 2006, 54:2392-2397.
43. Balunas M.J., Kinghorn A.D. Drug discovery from medicinal plants. Life Sci 2005, 78:431-441.
44. Kaur M., Singh R.P., Gu M., Agarwal R., Agarwal C. Grape seed extract inhibits invitro and invivo growth of human colorectal carcinoma cells. Clin Cancer Res 2006, 12:6194-6202.
45. Singh R.P., Tyagi A.K., Dhanalakshmi S., Agarwal R., Agarwal C. Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin like growth factor binding protein 3. Int J Cancer 2004, 108:733-740.
46. Kris-Etherton P.M., Hecker K.D., Bonanome A., Coval S.M., Binkoski A.E., Hilpert K.F., et al. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med 2002, 113:71-88.
47. Abdul K.F.J., Gallicano G., Mishra L. Colon cancer stem cells. Gastrointest Cancer Res 2010, S16-S23.
48. HungerNdThirst. Colon and rectal cancer: anatomy. Available from: . Accessed November 1, 2013. http://hungerndthirst.com/colon-and-rectal-cancer-anatomy/.
49. Booth C., Potten C.S. Gut instincts: thoughts on intestinal epithelial stem cells. J Clin Invest 2000, 105:1493-1500.
50. Potten C.S., Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990, 110:1001-1020.
51. Todaro M., Francipane M.G., Medema J.P., Stassi G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010, 138:2151-2162.
52. Brittan M., Wright N.A. Gastrointestinal stem cells. J Pathol 2002, 197:492-509.
53. D'Errico I., Moschetta A. Nuclear receptors, intestinal architecture and colon cancer: an intriguing link. Cell Mol Life Sci 2008, 65:1523-1543.
54. Humphries A., Wright N.A. Colonic crypt organization and tumorigenesis. Nat Rev Cancer 2008, 8:415-424.
55. Hennings H., Glick A.B., Greenhalgh D.A., Morgan D.L., Strickland J.E., Tennenbaum T., et al. Critical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesis. Proc Soc Exp Biol Med 1993, 202:1-8.
56. Tanaka T. Colorectal carcinogenesis: review of human and experimental animal studies. J Carcinog 2009, 8:5-19.
57. Roncucci L., Pedroni M., Vaccina F., Benatti P., Marzona L., De Pol A. Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell Prolif 2000, 33:1-18.
58. Swede H., Rohan T.E., Yu H., Anderson J.C., Stevens R.G., Brokaw J., et al. Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability. Cancer Causes Control 2009, 20:653-661.
59. Takayama T., Katsuki S., Takahashi Y., Ohi M., Nojiri S., Sakamaki S., et al. Aberrant Crypt Foci of the Colon as Precursors of Adenoma and Cancer. N Engl J Med 1998, 339:1277-1284.
60. Jass J.R., Whitehall V.L.J., Young J., Leggett B.A. Emerging concepts in colorectal neoplasia. Gastroenterology 2002, 123:862-876.
61. Smith G., Carey F.A., Beattie J., Wilkie M.J., Lightfoot T.J., Coxhead J., et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 2002, 99:9433-9438.
62. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
63. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319:525-532.
64. Davies R.J., Miller R., Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 2005, 5:199-209.
65. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. Network TCGA.
66. Pretlow T.P., Barrow B.J., Ashton W.S., O'Riordan M.A., Pretlow T.G., Jurcisek J.A., et al. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991, 51:1564-1567.
67. Sakai E., Takahashi H., Kato S., Uchiyama T., Hosono K., Endo H., et al. Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm. Cancer Epidemiol Biomarkers Prev 2011, 1918-1924.
68. Pretlow T.P., O'Riordan M.A., Somich G.A., Amini S.B., Pretlow T.G. Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis 1992, 13:1509-1512.
69. Guruswamy S., Swamy M.V., Choi C.I., Steele V.E., Rao C.V. S-adenosyl L-methionine inhibits azoxymethane-induced colonic aberrant crypt foci in F344 rats and suppresses human colon cancer Caco-2 cell growth in 3D culture. Int J Cancer 2008, 122:25-30.
70. Vanamala J., Leonardi T., Patil B.S., Taddeo S.S., Murphy M.E., Pike L.M., et al. Suppression of colon carcinogenesis by bioactive compounds in grapefruit. Carcinogenesis 2006, 27:1257-1265.
71. Heyer J., Yang K., Lipkin M., Edelmann W., Kucherlapati R. Mouse models for colorectal cancer. Oncogene 1999, 18:5325-5333.
72. Perse M., Cerar A. Morphological and molecular alterations in 1,2 dimethylhydrazine and azoxymethane induced colon carcinogenesis in rats. J Biomed Biotechnol 2011, 1-14.
73. Corpet D.E., Pierre F. Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003, 12:391-405.
74. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1997, 1332:F127-F147.
75. Robertis M.D., Massi E., Poeta M.L., Carotti S., Morini S., Cecchetelli L., et al. The AOM/DSS murine model for the study of colon carcinogenesis: from pathways to diagnosis and therapy studies. J Carcinog 2011, 10:9-35.
76. Takahashi M., Nakatsugi S., Sugimura T., Wakabayashi K. Frequent mutations of the β-catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 2000, 21:1117-1120.
77. Femia A.P., Caderni G. Rodent models of colon carcinogenesis for the study of chemopreventive activity of natural products. Planta Med 2008, 74:1602-1607.
78. Yamada Y., Yoshimi N., Hirose Y., Kawabata K., Matsunaga K., Shimizu M., et al. Frequent β-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res 2000, 60:3323-3327.
79. Corpet D.E., Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer 2005, 41:1911-1922.
80. Gamberini M., Cidade M.R., Valotta L.A., Armelin M., Leite L. Contribution of hydrazines-derived alkyl radicals to cytotoxicity and transformation induced in normal c-myc-overexpressing mouse fibroblasts. Carcinogenesis 1998, 19:147-155.
81. Mathison B.H., Murphy S.E., Shank R.C. Hydralazine and other hydrazine derivatives and the formation of DNA adducts. Toxicol Appl Pharmacol 1994, 127:91-98.
82. Yeung T.M., Chia L.A., Kosinski C.M., Kuo C.J. Regulation of self-renewal and differentiation by the intestinal stem cell niche. Cell Mol Life Sci 2011, 68:2513-2523.
83. Neumüller R.A., Knoblich J.A. Dividing cellular asymmetry: asymmetric cell division and its implications for stem cells and cancer. Genes Dev 2009, 23:2675-2699.
84. Vaiopoulos A.G., Kostakis I.D., Koutsilieris M., Papavassiliou A.G. Colorectal cancer stem cells. Stem Cells 2012, 30:363-371.
85. McDonald S.A., Preston S.L., Lovell M.J., Wright N.A., Jankowski J.A. Mechanisms of disease: from stem cells to colorectal cancer. Nat Clin Pract Gastroenterol Hepatol 2006, 3:267-274.
86. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010, 120:41-50.
87. Lugli A., Iezzi G., Hostettler I., Muraro M.G., Mele V., Tornillo L., et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010, 103:382-390.
88. Ricci-Vitiani L., Fabrizi E., Palio E., De Maria R. Colon cancer stem cells. J Mol Med 2009, 87:1097-1104.
89. Medema J.P. Cancer stem cells: the challenges ahead. Nat Cell Biol 2013, 15:338-344.
90. Kim K.M., Shibata D. Methylation reveals a niche: stem cell succession in human colon crypts. Oncogene 2002, 21:5441-5449.
91. Walker M., Patel K., Stappenbeck T. The stem cell niche. J Pathol 2009, 217:169-180.
92. Kuhnert F., Davis C.R., Wang H.T., Chu P., Lee M., Yuan J., et al. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc Natl Acad Sci U S A 2004, 101:266-271.
93. Takahashi H., Ishii H., Nishida N., Takemasa I., Mizushima T., Ikeda M., et al. Significance of Lgr5+ ve cancer stem cells in the colon and rectum. Ann Surg Oncol 2011, 1-9.
94. Haegebarth A., Clevers H. Wnt Signaling, Lgr5, and stem cells in the intestine and skin. Am J Pathol 2009, 174:715-721.
95. Clarke A. Wnt signalling in the mouse intestine. Oncogene 2006, 25:7512-7521.
96. Pacheco, MacLeod R.J. CaSR stimulates secretion of Wnt5a from colonic myofibroblasts to stimulate CDX2 and sucrase-isomaltase using Ror2 on intestinal epithelia. Am J Physiol-Gastr L 2008, 295:G748-G759.
97. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850.
98. Barker N., Ridgway R.A., van Es J.H., van de Wetering M., Begthel H., van den Born M., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2008, 457:608-611.
99. Dalerba P., Dylla S.J., Park I.-K., Liu R., Wang X., Cho R.W., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007, 104:10158-10163.
100. Sanders M., Majumdar A. Colon cancer stem cells: implications in carcinogenesis. Front Biosci 2011, 16:1651-1662.
101. Vermeulen L., Todaro M., de Sousa Mello F., Sprick M.R., Kemper K., Perez Alea M., et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 2008, 105:13427-13432.
102. Saif M.W., Chu E. Biology of Colorectal Cancer. Cancer J 2010, 16:196-201.
103. Emmink B.L., Verheem A., Van Houdt W.J., Steller E.J., Govaert K.M., Pham T.V., et al. The secretome of colon cancer stem cells contains drug-metabolizing enzymes. J Proteomics 2013, 91:84-96.
104. Jaks V., Barker N., Kasper M., van Es J.H., Snippert H.J., Clevers H., et al. Lgr5 marks cycling, yet long-lived, hair follicle stem cells. Nat Genet 2008, 40:1291-1299.
105. Sasaki Y., Kosaka H., Usami K., Toki H., Kawai H., Shiraishi N., et al. Establishment of a novel monoclonal antibody against LGR5. Biochem Biophys Res Com 2010, 394:498-502.
106. Korchagin K. Neoplastic diseases reviews. 2009-2010. Available from . Accessed November 10, 2013. http://www.cancerlink.ru/enintestinalstemcells.html.
107. Walker F., Zhang H.-H., Odorizzi A., Burgess A.W. LGR5 Is a negative regulator of tumourigenicity, antagonizes Wnt signalling and regulates cell adhesion in colorectal cancer cell lines. PLoS One 2011, 6:e22733.
108. Morita H., Mazerbourg S., Bouley D.M., Luo C.W., Kawamura K., Kuwabara Y., et al. Neonatal lethality of LGR5 null mice is associated with ankyloglossia and gastrointestinal distension. Mol Cell Biol 2004, 24:9736-9743.
109. Garcia M.I., Ghiani M., Lefort A., Libert F., Strollo S., Vassart G. LGR5 deficiency deregulates Wnt signaling and leads to precocious Paneth cell differentiation in the fetal intestine. Dev Biol 2009, 331:58-67.
110. Takeda K., Kinoshita I., Shimizu Y., Matsuno Y., Shichinohe T., Dosaka-Akita H. Expression of Lgr5, an intestinal stem cell marker, during each stage of colorectal tumorigenesis. Anticancer Res 2011, 31:263-270.
111. Yamamoto Y., Sakamoto M., Fujii G., Tsuiji H., Kenetaka K., Asaka M., et al. Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with β-catenin mutations. Hepatol 2003, 37:528-533.
112. McClanahan T., Koseoglu S., Smith K., Grein J., Gustafson E., Black S., et al. Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol Ther 2006, 5:419-426.
113. Becker L., Huang Q., Mashimo H. Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma. Dis Esophagus 2010, 23:168-174.
114. Merlos-Suarez A., Barriga F.M., Jung P., Iglesias M., Cespedes M.V., Rossell D., et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011, 8:511-524.
115. Yoon J.K., Lee J.S. Cellular signaling and biological functions of R-spondins. Cell Signal 2012, 24:369-377.
116. Vasiliou V., Pappa A., Estey T. Role of human aldehyde dehydrogenases inendobiotic and xenobiotic metabolism. Drug Metab Rev 2004, 36:279-299.
117. Stagos D., Chen Y., Brocker C., Donald E., Jackson B.C., Orlicky D.J., et al. Aldehyde dehydrogenase 1B1: molecular cloning and characterization of a novel mitochondrial acetaldehyde-metabolizing enzyme. Drug Metab Dispos 2010, 38:1679-1687.
118. Langan R.C., Mullinax J.E., Ray S., Raiji M.T., Schaub N., Xin H.W., et al. A pilot study assessing the potential role of non-CD133 colorectal cancer stem cells as biomarkers. J Cancer 2012, 3:231-240.
119. Madka V., Rao C.V. Cancer stem cell markers as potential targets for epithelial cancers. Indian J Exp Biol 2011, 49:826-835.
120. Qiu W., Wang X., Leibowitz B., Liu H., Barker N., Okada H., et al. Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc Natl Acad Sci U S A 2010, 107:20027-20032.
121. Gonzalez C.A., Riboli E. Diet and cancer prevention: contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Cancer 2010, 46:2555-2562.
122. Bingham S., Riboli E. Diet and cancer-the European Prospective Investigation into Cancer and Nutrition. Nat Rev Cancer 2004, 4:206-215.
123. Bingham S.A., Norat T., Moskal A., Ferrari P., Slimani N., Clavel-Chapelon F., et al. Is the association with fiber from foods in colorectal cancer confounded by folate intake?. Cancer Epidemiol Biomarkers Prev 2005, 14:1552-1556.
124. Jenab M., Bueno-de-Mesquita H.B., Ferrari P., van Duijnhoven F.J., Norat T., Pischon T., et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study. BMJ 2010, 340:b5500.
125. Riboli E., Hunt K.J., Slimani N., Ferrari P., Norat T., Fahey M., et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002, 5:1113-1124.
126. van Duijnhoven F.J.B., Bueno-De-Mesquita H.B., Ferrari P., Jenab M., Boshuizen H.C., Ros M.M., et al. Fruit, vegetables, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2009, 89:1441-1452.
127. Norat T., Bingham S., Ferrari P., Slimani N., Jenab M., Mazuir M., et al. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst 2005, 97:906-916.
128. American Institute for Cancer Research. Food, nutrition, physical activity and the prevention of cancer: a global perspective,2007.
129. Risio M., Lipkin M., Newmark H., Yang K., Rossini F.P., Steele V.E., et al. Apoptosis, cell replication, and Western-style diet-induced tumorigenesis in mouse colon. Cancer Res 1996, 56:4910-4916.
130. McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk?. Cancer Epidemiol Biomarkers Prev 1994, 3:687-695.
131. Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995, 6:164-179.
132. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4:579-591.
133. Olivo Marston S.E., Hursting S.D., Lavigne J., Perkins S.N., Maarouf R.S., Yakar S., et al. Genetic reduction of circulating insulin like growth factor 1 inhibits azoxymethane induced colon tumorigenesis in mice. Mol Carcinogenesis 2009, 48:1071-1076.
134. Giouleme O., Diamantidis M.D., Katsaros M.G. Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J Gastroenterol 2011, 17:444-448.
135. Tran T.T., Medline A., Bruce W.R. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 1996, 5:1013-1015.
136. Tran T.T., Naigamwalla D., Oprescu A.I., Lam L., McKeown-Eyssen G., Bruce W.R., et al. Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation invivo. Endocrinol 2006, 147:1830-1837.
137. Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
138. Padidar S., Farquharson A., Williams L., Kearney R., Arthur J., Drew J. High-fat dietalters gene expression in the liver and colon: links to increased development of aberrant crypt foci. Dig Dis Sci 2012, 57:1866-1874.
139. Karmiris K., Koutroubakis I.E., Kouroumalis E.A. The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:847-855.
140. Aparicio T., Kotelevets L., Tsocas A., Laigneau J.-P., Sobhani I., Chastre E., et al. Leptin stimulates the proliferation of human colon cancer cells invitro but does not promote the growth of colon cancer xenografts innude mice or intestinal tumorigenesis in ApcMin/+ mice. Gut 2005, 54:1136-1145.
141. Fantuzzi G., Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukocyte Biol 2000, 68:437-446.
142. Liu Z., Uesaka T., Watanabe H., Kato N. High fat diet enhances colonic cell proliferation and carcinogenesis in rats by elevating serum leptin. Int J Oncol 2001, 19:1009-1014.
143. Bartucci M., Svensson S., Ricci-Vitiani L., Dattilo R., Biffoni M., Signore M., et al. Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells. Endocr Relat Cancer 2010, 17:823-833.
144. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
145. Singletary K.W., Meline B. Effect of grape seed proanthocyanidins on colon aberrant crypts and breast tumors in a rat dual-organ tumor model. Nutr Cancer 2001, 39:252-258.
146. Medicine NCFCAA. Grape Seed Extract. NCCAM Publication No: D370; 2012. Available from . Accessed November 15, 2013. http://nccam.nih.gov/health/grapeseed/ataglance.htm.